Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00553787 · ClinicalTrials.gov registry record · Phase 3
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
A Phase 3 study of Obesity and Type 2 Diabetes, sponsored by VIVUS.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,487
- Enrollment target
- 6
- Study locations
NCT00553787: Completed Phase 3 study of Obesity and Type 2 Diabetes, sponsored by VIVUS.
NCT00553787 is a Phase 3 study of Obesity and Type 2 Diabetes that has completed, run by VIVUS. The registered enrollment target is 2,487 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (204% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00553787, a Phase 3 study of Obesity and Type 2 Diabetes, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,487 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.
Conditions Studied
Interventions
- DRUG VI-0521
Study Locations (6)
Alabama
- Research Site - Birmingham
Connecticut
- Research Site - Ridgefield
New York
- Research Site - New York
North Carolina
- Research Site - Durham
Ohio
- Research Site - Toledo
Texas
- Research Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,487 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00553787 record still lists
NCT00553787 is an interventional study that assigns participants to a tested intervention. Its 2,487 participants enrollment target places it among the larger protocols in the corpus, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (204% higher).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which VI-0521 is the first listed.
NCT00553787 lists 6 locations in 6 states (Alabama, Connecticut, New York).
Frequently Asked Questions
What is clinical trial NCT00553787 about?
NCT00553787 is a clinical study titled "Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions". The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.
What is the current status of trial NCT00553787?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,487 participants. The study started on 2007-11. Estimated completion is 2009-06.
What conditions does trial NCT00553787 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes.
What interventions are being tested in trial NCT00553787?
The interventions under investigation include: VI-0521 (DRUG).
Who is sponsoring clinical trial NCT00553787?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00553787 being conducted?
This trial has 6 study locations across Alabama, Connecticut, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00553787's enrollment target sits among peer trials
2,487 38th of 1053 higher than 1,016 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia